Paratek Pharmaceuticals, Inc. (PRTK)
| Previous Close | 2.1100 |
| Open | 2.1000 |
| Bid | 2.1000 x 1000 |
| Ask | 2.1100 x 900 |
| Day's Range | 2.0850 - 2.1350 |
| 52 Week Range | 1.6000 - 4.3700 |
| Volume | |
| Avg. Volume | 379,306 |
| Market Cap | 115.821M |
| Beta (5Y Monthly) | 1.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1780 |
| Earnings Date | Mar 13, 2023 - Mar 17, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Oct 31, 2014 |
| 1y Target Est | 17.50 |
- GlobeNewswire
Paratek Pharmaceuticals Announces Inclusion of NUZYRA® (omadacycline) in China’s National Reimbursement Drug List (NRDL)
National Healthcare Security Administration Adds NUZYRA to NRDL for Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure InfectionsBOSTON, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that China’s National Healthcare Security Administration (NHSA) has added the intravenous (IV) formulation of NUZYRA® (omadacycline) to the country’s National Reimbursement Drug List (NRDL) for treatment of community-acquir
- GlobeNewswire
Paratek Pharmaceuticals Receives $36.4 Million Milestone Payment Associated with the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield Contract
Total Procurement-related Revenue Recognition of $38.1 Million to Paratek in December 2022Procurement Triggered by Positive Top-Line Data from Pilot Efficacy Study of NUZYRA for the Treatment of Pulmonary Anthrax Announced in December BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) today announced the receipt of a $36.4 million milestone payment associated with the second procurement of NUZYRA® (omadacycline) under the company’s Project BioShield contract w
- Simply Wall St.
Individual investors account for 39% of Paratek Pharmaceuticals, Inc.'s (NASDAQ:PRTK) ownership, while institutions account for 38%
If you want to know who really controls Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ), then you'll have to look at the...
